These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 32170135)
1. Establishment, optimisation and quantitation of a bioluminescent murine infection model of visceral leishmaniasis for systematic vaccine screening. Ong HB; Clare S; Roberts AJ; Wilson ME; Wright GJ Sci Rep; 2020 Mar; 10(1):4689. PubMed ID: 32170135 [TBL] [Abstract][Full Text] [Related]
2. Intranasal vaccine from whole Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis. Helou DG; Mauras A; Fasquelle F; Lanza JS; Loiseau PM; Betbeder D; Cojean S PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009627. PubMed ID: 34403413 [TBL] [Abstract][Full Text] [Related]
3. Identification of Leishmania infantum chagasi proteins in urine of patients with visceral leishmaniasis: a promising antigen discovery approach of vaccine candidates. Kashino SS; Abeijon C; Qin L; Kanunfre KA; Kubrusly FS; Silva FO; Costa DL; Campos D; Costa CH; Raw I; Campos-Neto A Parasite Immunol; 2012 Jul; 34(7):360-71. PubMed ID: 22443237 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic immunization with radio-attenuated Leishmania parasites through i.m. route revealed protection against the experimental murine visceral leishmaniasis. Datta S; Manna M; Khanra S; Ghosh M; Bhar R; Chakraborty A; Roy S Parasitol Res; 2012 Jul; 111(1):361-9. PubMed ID: 22437790 [TBL] [Abstract][Full Text] [Related]
5. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis. Das P; Paik D; Naskar K; Chakraborti T Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116 [TBL] [Abstract][Full Text] [Related]
7. IL-4 contributes to failure, and colludes with IL-10 to exacerbate Leishmania donovani infection following administration of a subcutaneous leishmanial antigen vaccine. Bhowmick S; Ravindran R; Ali N BMC Microbiol; 2014 Jan; 14():8. PubMed ID: 24428931 [TBL] [Abstract][Full Text] [Related]
8. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice. Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis. Thakur A; Kaur H; Kaur S Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605 [TBL] [Abstract][Full Text] [Related]
10. Genetically Engineered Ascorbic acid-deficient Live Mutants of Leishmania donovani induce long lasting Protective Immunity against Visceral Leishmaniasis. Anand S; Madhubala R Sci Rep; 2015 Jun; 5():10706. PubMed ID: 26035062 [TBL] [Abstract][Full Text] [Related]
11. Systematic identification of genes encoding cell surface and secreted proteins that are essential for in vitro growth and infection in Leishmania donovani. Roberts AJ; Ong HB; Clare S; Brandt C; Harcourt K; Franssen SU; Cotton JA; Müller-Sienerth N; Wright GJ PLoS Pathog; 2022 Feb; 18(2):e1010364. PubMed ID: 35202447 [TBL] [Abstract][Full Text] [Related]
12. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity. Choudhury R; Das P; De T; Chakraborti T Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312 [TBL] [Abstract][Full Text] [Related]
13. miR-21 Expression Determines the Early Vaccine Immunity Induced by Gannavaram S; Bhattacharya P; Siddiqui A; Ismail N; Madhavan S; Nakhasi HL Front Immunol; 2019; 10():2273. PubMed ID: 31608064 [TBL] [Abstract][Full Text] [Related]
14. Reduced pathogenicity of fructose-1,6-bisphosphatase deficient Leishmania donovani and its use as an attenuated strain to induce protective immunogenicity. Saini S; Ghosh AK; Das S; Singh R; Abhishek K; Verma S; Kumar A; Mandal A; Purkait B; Sinha KK; Das P Vaccine; 2018 Feb; 36(9):1190-1202. PubMed ID: 29395522 [TBL] [Abstract][Full Text] [Related]
15. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route. Ravindran R; Maji M; Ali N Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194 [TBL] [Abstract][Full Text] [Related]
16. Single dose novel Salmonella vaccine enhances resistance against visceralizing L. major and L. donovani infection in susceptible BALB/c mice. Schroeder J; Brown N; Kaye P; Aebischer T PLoS Negl Trop Dis; 2011 Dec; 5(12):e1406. PubMed ID: 22216363 [TBL] [Abstract][Full Text] [Related]
17. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection. Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant effects of TLR agonist gardiquimod admixed with Leishmania vaccine in mice model of visceral leishmaniasis. Goyal DK; Keshav P; Kaur S Infect Genet Evol; 2021 Sep; 93():104947. PubMed ID: 34052416 [TBL] [Abstract][Full Text] [Related]
19. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides. Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073 [TBL] [Abstract][Full Text] [Related]